In the present study, we aimed to investigate the availability and affordability of osteoporosis (OP) treatment drugs in Wuhan and provide references for policymakers. We used the WHO/HAI standardization method to investigate the OP drug in Wuhan and collected drug information for statistical analysis to evaluate the availability and affordability. The results showed that the availability of bisphosphonates, active vitamin D, and their analogs was relatively high; the availability of denosumab, salmon calcitonin, and teriparatide was general; and the availability of calcitonin, raloxifene, and strontium ranelate was low. In terms of affordability, alendronate generic drugs had good affordability, while the other 10 OP treatment drugs had poor affordability. Generally, the overall availability of OP treatment drugs in Wuhan was average, and the affordability was poor. As China’s aging problem intensified, relevant government departments might consider including more OP treatment drugs in the medical insurance catalog and concentrating their quantities in the procurement process to further improve the availability and affordability of OP treatment drugs.